Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Scientific and Technical Instruments

Mesa Laboratories, Inc. acquires, develops, manufactures, and markets electronic measurement instruments used by industrial and hemodialysis customers. The Company"s products include pipeline flow meters and instruments used for calibrating hemodialysis and proportioning equipment, temperature sensors, and data recorders. Mesa is also exploring alternative uses of their technologies.
Website: mesalabs.com



Growth: Bad revenue growth rate -1.9%, there is slowdown compared to average historical growth rates 20.6%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +19.7%. On average the margin is decreasing unsteadily. Gross margin is high, +62.5%. In the last quarter the company did not beat the estimated EPS, -70.3%. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.37 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.6%. Free cash flow yield -0.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 36.6% higher than minimum and 65.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.2x by EV / Sales multiple , the company can be 13.2% overvalued

Key Financials (Download financials)

Ticker: MLAB
Share price, USD:  (+1.9%)115.5
year average price 113.30  


year start price 161.32 2023-05-08

max close price 161.32 2023-05-08

min close price 84.55 2023-11-13

current price 115.50 2024-05-06
Common stocks: 5 297 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.8%
EV / LTM EBITDA: 18.6x
EV / EBITDA annualized: 13.0x
Last revenue growth (y/y):  -1.9%
Last growth of EBITDA (y/y):  -16.7%
Historical revenue growth:  20.6%
Historical growth of EBITDA:  27.2%
EV / Sales: 3.7x
Margin (EBITDA LTM / Revenue): 19.7%
Fundamental value created in LTM:
Market Cap ($m): 612
Net Debt ($m): 168
EV (Enterprise Value): 780
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-08Zacks Investment Research

Best Value Stocks to Buy for April 8th

2024-04-01GlobeNewsWire

Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024

2023-12-14GlobeNewsWire

Mesa Laboratories, Inc. to Announce Second Quarter Results on February 5, 2024

2023-09-22Zacks Investment Research

Bear of the Day: Mesa Labs (MLAB)

2023-09-13GlobeNewsWire

Mesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2023

2023-06-21GlobeNewsWire

Mesa Laboratories, Inc. to Announce First Quarter Results on August 3, 2023

2023-05-25Zacks Investment Research

Mesa Labs (MLAB) Q4 Earnings and Revenues Miss Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MLAB MLAB MLAB MLAB MLAB MLAB
reportedCurrency USD USD USD USD USD USD
cik 724 004 724 004 724 004 724 004 724 004 724 004
fillingDate 2024-02-05 2023-11-06 2023-08-03 2023-05-30 2023-02-06 2022-11-03
acceptedDate 2024-02-05 08:01:38 2023-11-06 08:00:52 2023-08-03 08:00:58 2023-05-30 08:01:03 2023-02-06 08:00:41 2022-11-03 08:01:16
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 53M 53M 51M 56M 54M 59M
costOfRevenue 20M 21M 19M 22M 22M 22M
grossProfit 33M 32M 31M 33M 33M 36M
grossProfitRatio 0.625 0.604 0.616 0.597 0.604 0.619
researchAndDevelopmentExpenses 4M 5M 5M 5M 5M 5M
generalAndAdministrativeExpenses 19M 18M 18M 18M 16M 18M
sellingAndMarketingExpenses 10M 10M 9M 10M 8M 9M
sellingGeneralAndAdministrativeExpenses 29M 27M 27M 28M 25M 27M
otherExpenses 4M -360 000 775 000 -794 000 -324 000 0
operatingExpenses 33M 32M 32M 33M 29M 32M
costAndExpenses 54M 53M 51M 55M 51M 55M
interestIncome 0 905 000 0 0 0 0
interestExpense 2M 905 000 1M 794 000 1M 1M
depreciationAndAmortization 9M 8M 8M 9M 8M 9M
ebitda 13M 8M 8M 517 000 12M 13M
ebitdaratio 0.240 0.144 0.163 0.009 0.215 0.215
operatingIncome -67 000 -60 000 -664 000 -9M 3M 4M
operatingIncomeRatio -0.001 -0.001 -0.013 -0.154 0.063 0.068
totalOtherIncomeExpensesNet 4M -360 000 775 000 8M -1M -611 000
incomeBeforeTax 2M -1M -937 000 -277 000 2M 3M
incomeBeforeTaxRatio 0.036 -0.025 -0.019 -0.005 0.035 0.058
incomeTaxExpense -170 000 -95 000 -388 000 -888 000 1M 2M
netIncome 2M -1M -549 000 611 000 451 000 1M
netIncomeRatio 0.040 -0.023 -0.011 0.011 0.008 0.022
eps 0.390 -0.230 -0.100 0.110 0.080 0.250
epsdiluted 0.390 -0.230 -0.100 0.110 0.080 0.240
weightedAverageShsOut 5M 5M 5M 5M 5M 5M
weightedAverageShsOutDil 5M 5M 5M 5M 5M 5M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MLAB MLAB MLAB MLAB MLAB MLAB
reportedCurrency USD USD USD USD USD USD
cik 724 004 724 004 724 004 724 004 724 004 724 004
fillingDate 2024-02-05 2023-11-06 2023-08-03 2023-05-30 2023-02-06 2022-11-03
acceptedDate 2024-02-05 08:01:38 2023-11-06 08:00:52 2023-08-03 08:00:58 2023-05-30 08:01:03 2023-02-06 08:00:41 2022-11-03 08:01:16
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 28M 36M 32M 33M 26M 32M
shortTermInvestments 2M 2M 0 0 0 0
cashAndShortTermInvestments 28M 36M 32M 33M 26M 32M
netReceivables 36M 36M 36M 43M 42M 42M
inventory 36M 33M 36M 35M 34M 28M
otherCurrentAssets 5M 4M 4M 86M 3M 4M
totalCurrentAssets 118M 118M 115M 119M 114M 116M
propertyPlantEquipmentNet 32M 29M 28M 28M 28M 28M
goodwill 346M 283M 284M 286M 286M 278M
intangibleAssets 233M 198M 205M 217M 223M 222M
goodwillAndIntangibleAssets 579M 481M 489M 503M 509M 500M
longTermInvestments 0 0 0 0 0 0
taxAssets 1M 1M 1M 1M 708 000 647 000
otherNonCurrentAssets 12M 9M 10M 10M 11M 11M
totalNonCurrentAssets 623M 520M 528M 543M 549M 540M
otherAssets 0 0 0 0 0 0
totalAssets 742M 637M 643M 662M 663M 656M
accountPayables 5M 5M 6M 6M 6M 8M
shortTermDebt 3M 3M 3M 3M 0 0
taxPayables 11M 8M 8M 9M 2M 1M
deferredRevenue 14M 14M 15M 16M 15M 14M
otherCurrentLiabilities 22M 18M 15M 19M 21M 20M
totalCurrentLiabilities 44M 40M 39M 43M 42M 42M
longTermDebt 233M 171M 176M 183M 189M 197M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 44M 33M 34M 34M 37M 37M
otherNonCurrentLiabilities 17M 5M 7M 8M 8M 219M
totalNonCurrentLiabilities 295M 210M 216M 225M 234M 240M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 3M 3M 3M 3M 0 0
totalLiabilities 339M 249M 255M 268M 276M 282M
preferredStock 0 0 0 0 0 0
commonStock 341M 338M 334M 332M 327M 325M
retainedEarnings 72M 71M 73M 74M 74M 75M
accumulatedOtherComprehensiveIncomeLoss -10M -21M -19M -13M -14M -26M
othertotalStockholdersEquity 0 0 0 0 0 0
totalStockholdersEquity 403M 388M 388M 393M 387M 374M
totalEquity 403M 388M 388M 393M 387M 374M
totalLiabilitiesAndStockholdersEquity 742M 637M 643M 662M 663M 656M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 742M 637M 643M 662M 663M 656M
totalInvestments 2M 2M 0 0 0 0
totalDebt 236M 174M 178M 186M 189M 197M
netDebt 208M 138M 146M 153M 163M 164M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MLAB MLAB MLAB MLAB MLAB MLAB
reportedCurrency USD USD USD USD USD USD
cik 724 004 724 004 724 004 724 004 724 004 724 004
fillingDate 2024-02-05 2023-11-06 2023-08-03 2023-05-30 2023-02-06 2022-11-03
acceptedDate 2024-02-05 08:01:38 2023-11-06 08:00:52 2023-08-03 08:00:58 2023-05-30 08:01:03 2023-02-06 08:00:41 2022-11-03 08:01:16
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome 2M -1M -549 000 611 000 451 000 1M
depreciationAndAmortization 9M 8M 8M 9M 9M 8M
deferredIncomeTax 0 0 -5M 908 000 0 0
stockBasedCompensation 3M 3M 3M 3M 2M 4M
changeInWorkingCapital -103 000 -1M -1M 2M -4M -5M
accountsReceivables 3M -1M 6M -142 000 678 000 -1M
inventory 401 000 1M -1M -991 000 -5M -1M
accountsPayables -349 000 -768 000 -539 000 -206 000 -2M 448 000
otherWorkingCapital -3M -642 000 -6M 3M 2M -2M
otherNonCashItems -3M 1M 5M -3M 733 000 1M
netCashProvidedByOperatingActivities 12M 10M 10M 13M 8M 11M
investmentsInPropertyPlantAndEquipment -1M -634 000 -270 000 -1M -2M -2M
acquisitionsNet -80M 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 -5M 0
netCashUsedForInvestingActivites -81M -634 000 -270 000 -1M -7M -2M
debtRepayment -9M -5M -8M -6M -8M -20M
commonStockIssued 2000.000 304 000 0 -1M 0 0
commonStockRepurchased -2000.000 -2000.000 0 -564 000 0 0
dividendsPaid -862 000 -862 000 -859 000 -856 000 -855 000 -852 000
otherFinancingActivites 71M -2000.000 -660 000 4M -28 000 2M
netCashUsedProvidedByFinancingActivities 61M -6M -10M -4M -9M -19M
effectOfForexChangesOnCash 1M -341 000 -684 000 -292 000 1M -2M
netChangeInCash -7M 3M -534 000 7M -6M -11M
cashAtEndOfPeriod 28M 36M 32M 33M 26M 32M
cashAtBeginningOfPeriod 36M 32M 33M 26M 32M 44M
operatingCashFlow 12M 10M 10M 13M 8M 11M
capitalExpenditure -1M -634 000 -270 000 -1M -2M -2M
freeCashFlow 10M 9M 10M 11M 6M 9M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-02-05 13:00 ET
Mesa Labs Announces Third Quarter Results
2024-01-08 13:00 ET
Mesa Laboratories Appoints Mark Capone to its Board of Directors
2024-01-04 20:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2024-01-03 13:00 ET
Mesa Labs Completes the Acquisition of GKE Science & Technology Co.
2023-12-14 15:47 ET
Mesa Laboratories, Inc. to Announce Second Quarter Results on February 5, 2024
2023-11-06 13:00 ET
Mesa Labs Announces Second Quarter Results
2023-10-16 07:00 ET
Mesa Labs Acquires GKE-GmbH Complementary Sterilization Indicators and Healthcare Channels to Mesa’s SDC Platform
2023-10-03 12:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2023-09-13 17:37 ET
Mesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2023
2023-08-24 20:02 ET
Mesa Laboratories, Inc. Announces Commitment to Disclose Scope 1 and 2 Greenhouse Gas Emissions
2023-08-03 12:00 ET
Mesa Labs Announces First Quarter Results
2023-07-05 19:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2023-06-21 15:50 ET
Mesa Laboratories, Inc. to Announce First Quarter Results on August 3, 2023
2023-05-25 12:00 ET
Mesa Labs Announces Unaudited Fourth Quarter and Full Fiscal Year 2023 Results
2023-04-03 22:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2023-03-13 12:00 ET
Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure
2023-03-09 13:00 ET
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year 2023 Results on May 25, 2023
2023-02-13 13:00 ET
Mesa Labs Releases Environmental, Social, and Governance Program Brochure
2023-02-06 13:36 ET
Mesa Labs Announces Third Quarter Results
2023-01-03 22:00 ET
Mesa Labs Declares Quarterly Dividend
2022-12-16 16:59 ET
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 6, 2023
2022-11-17 13:04 ET
Mesa Labs Acquires Belyntic’s Peptide Purification Business
2022-11-04 19:49 ET
Mesa Laboratories, Inc. Appoints Shiraz Ladiwala as Lead Independent Director
2022-11-03 12:00 ET
Mesa Labs Announces Second Quarter Results
2022-10-03 18:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2022-08-04 12:00 ET
Mesa Labs Announces First Quarter Results
2022-07-06 23:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2022-06-27 12:01 ET
Mesa Laboratories Appoints Tony Tripeny to its Board of Directors
2022-05-31 12:00 ET
Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results
2022-04-06 17:10 ET
Mesa Labs Declares Quarterly Dividend
2022-02-03 13:00 ET
Mesa Labs Announces Third Quarter Results
2022-01-06 20:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2021-11-04 12:00 ET
Mesa Labs Announces Second Quarter Results
2021-10-29 12:00 ET
Leader in Corporate Development and Strategy Joins Mesa Labs Board of Directors
2021-10-20 16:05 ET
Mesa Labs Closes Acquisition of Agena Bioscience
2021-10-01 19:00 ET
Mesa Labs Declares Quarterly Dividend
2021-09-14 11:00 ET
Mesa Labs Announces Agreement to Acquire Agena Bioscience, Inc.
2021-08-05 12:00 ET
Mesa Labs Announces First Quarter Results
2021-07-06 23:19 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2021-06-01 12:00 ET
Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results
2021-04-05 21:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2021-02-03 13:00 ET
Mesa Labs Reports Third Quarter Results for FY21
2021-01-05 22:00 ET
Mesa Labs Declares Quarterly Dividend
2020-11-05 13:00 ET
Mesa Labs Reports Second Quarter Results for FY21
2020-10-01 20:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2020-08-06 12:00 ET
Mesa Labs Reports First Quarter Results
2020-07-06 16:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2020-06-16 15:52 ET
Mesa Laboratories, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock in Public Offering
2020-06-10 00:15 ET
Mesa Laboratories, Inc. Announces Upsizing and Pricing of Public Offering of Common Stock
2020-06-08 20:01 ET
Mesa Laboratories, Inc. Announces Proposed Public Offering of Common Stock
2020-06-01 12:00 ET
Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results
2020-05-15 12:00 ET
Life Sciences Executive Shannon Hall Joins Mesa Labs Board of Directors
2020-04-01 22:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2020-02-10 13:00 ET
Mesa Labs Reports Third Quarter Results
2020-01-10 00:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND
2019-11-06 13:00 ET
Mesa Labs Reports Record Second Quarter Revenues and Adjusted Operating Income
2019-11-01 00:55 ET
Mesa Labs Acquires Gyros Protein Technologies
2019-10-01 21:00 ET
MESA LABS DECLARES QUARTERLY DIVIDEND

SEC forms

Show financial reports only

SEC form 8
2024-02-05 00:00 ET
Mesa Laboratories published news for 2023 q4
SEC form 8
2024-02-05 00:00 ET
Mesa Laboratories reported for 2023 q4
SEC form 10
2024-02-05 00:00 ET
Mesa Laboratories reported for 2023 q4
SEC form 10
2023-11-06 08:00 ET
Mesa Laboratories reported for 2023 q3
SEC form 8
2023-11-06 08:00 ET
Mesa Laboratories published news for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Mesa Laboratories published news for 2023 q3
SEC form 10
2023-08-03 08:00 ET
Mesa Laboratories reported for 2023 q2
SEC form 6
2023-08-03 08:00 ET
Mesa Laboratories published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Mesa Laboratories published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Mesa Laboratories published news for 2023 q2
SEC form 6
2023-07-14 08:00 ET
Mesa Laboratories published news for 2023 q2
SEC form 6
2023-07-03 10:27 ET
Mesa Laboratories published news for 2023 q2
SEC form 10
2023-05-30 00:00 ET
Mesa Laboratories published news for 2023 q1
SEC form 6
2023-05-25 08:00 ET
Mesa Laboratories reported for 2023 q1
SEC form 8
2023-05-25 00:00 ET
Mesa Laboratories published news for 2023 q1
SEC form 6
2023-05-08 08:00 ET
Mesa Laboratories published news for 2023 q1
SEC form 6
2023-03-13 08:00 ET
Mesa Laboratories published news for 2022 q4
SEC form 6
2023-02-06 08:37 ET
Mesa Laboratories published news for 2022 q4
SEC form 10
2023-02-06 08:00 ET
Mesa Laboratories reported for 2022 q4
SEC form 8
2023-02-06 00:00 ET
Mesa Laboratories reported for 2022 q4
SEC form 10
2023-02-06 00:00 ET
Mesa Laboratories reported for 2022 q4
SEC form 6
2023-01-04 14:13 ET
Mesa Laboratories published news for 2022 q4
SEC form 6
2022-11-21 16:44 ET
Mesa Laboratories published news for 2022 q3
SEC form 6
2022-11-04 15:50 ET
Mesa Laboratories published news for 2022 q3
SEC form 6
2022-11-04 14:11 ET
Mesa Laboratories published news for 2022 q3
SEC form 6
2022-11-03 08:01 ET
Mesa Laboratories published news for 2022 q3
SEC form 10
2022-11-03 08:01 ET
Mesa Laboratories reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Mesa Laboratories reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Mesa Laboratories reported for 2022 q3
SEC form 6
2022-08-26 16:30 ET
Mesa Laboratories published news for 2022 q2
SEC form 6
2022-08-09 17:28 ET
Mesa Laboratories published news for 2022 q2
SEC form 10
2022-08-04 08:01 ET
Mesa Laboratories reported for 2022 q2
SEC form 6
2022-08-04 08:00 ET
Mesa Laboratories published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Mesa Laboratories reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Mesa Laboratories reported for 2022 q2
SEC form 6
2022-07-14 08:00 ET
Mesa Laboratories published news for 2022 q2
SEC form 6
2022-06-27 08:00 ET
Mesa Laboratories published news for 2022 q1
SEC form 10
2022-05-31 16:09 ET
Mesa Laboratories reported for 2022 q1
SEC form 6
2022-05-31 08:00 ET
Mesa Laboratories published news for 2022 q1
SEC form 10
2022-05-31 00:00 ET
Mesa Laboratories reported for 2022 q1
SEC form 8
2022-05-31 00:00 ET
Mesa Laboratories reported for 2022 q1
SEC form 6
2022-04-08 19:06 ET
Mesa Laboratories published news for 2022 q1
SEC form 6
2022-04-05 17:01 ET
Mesa Laboratories published news for 2022 q1
SEC form 6
2022-03-30 17:22 ET
Mesa Laboratories published news for 2021 q4
SEC form 10
2022-02-03 08:01 ET
Mesa Laboratories published news for 2021 q4
SEC form 6
2022-02-03 08:00 ET
Mesa Laboratories published news for 2021 q4
SEC form 10
2022-02-03 00:00 ET
Mesa Laboratories published news for 2021 q4
SEC form 8
2022-02-03 00:00 ET
Mesa Laboratories published news for 2021 q4
SEC form 6
2021-12-23 14:38 ET
Mesa Laboratories published news for 2021 q3
SEC form 6
2021-12-22 11:57 ET
Mesa Laboratories published news for 2021 q3
SEC form 6
2021-11-19 12:48 ET
Mesa Laboratories published news for 2021 q3
SEC form 10
2021-11-04 08:02 ET
Mesa Laboratories published news for 2021 q3
SEC form 6
2021-11-04 08:00 ET
Mesa Laboratories published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Mesa Laboratories published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Mesa Laboratories published news for 2021 q3
SEC form 6
2021-10-29 08:00 ET
Mesa Laboratories published news for 2021 q3
SEC form 6
2021-10-21 08:00 ET
Mesa Laboratories published news for 2021 q3
SEC form 6
2021-09-29 17:05 ET
Mesa Laboratories published news for 2021 q2
SEC form 6
2021-09-14 08:00 ET
Mesa Laboratories published news for 2021 q2
SEC form 6
2021-09-03 17:00 ET
Mesa Laboratories published news for 2021 q2
SEC form 6
2021-08-27 13:22 ET
Mesa Laboratories published news for 2021 q2
SEC form 10
2021-08-05 08:01 ET
Mesa Laboratories published news for 2021 q2
SEC form 6
2021-08-05 08:00 ET
Mesa Laboratories published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Mesa Laboratories published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Mesa Laboratories published news for 2021 q2
SEC form 6
2021-07-16 06:02 ET
Mesa Laboratories published news for 2021 q2
SEC form 10
2021-06-01 11:04 ET
Mesa Laboratories published news for 2021 q1
SEC form 6
2021-06-01 08:00 ET
Mesa Laboratories published news for 2021 q1
SEC form 8
2021-06-01 00:00 ET
Mesa Laboratories published news for 2021 q1
SEC form 10
2021-06-01 00:00 ET
Mesa Laboratories published news for 2021 q1
SEC form 6
2021-03-08 15:55 ET
Mesa Laboratories published news for 2020 q4
SEC form 10
2021-02-03 08:01 ET
Mesa Laboratories published news for 2020 q4
SEC form 6
2021-02-03 08:00 ET
Mesa Laboratories published news for 2020 q4
SEC form 6
2020-11-13 17:21 ET
Mesa Laboratories published news for 2020 q3
SEC form 6
2020-11-12 12:24 ET
Mesa Laboratories published news for 2020 q3
SEC form 10
2020-11-05 08:01 ET
Mesa Laboratories published news for 2020 q3
SEC form 6
2020-11-05 08:00 ET
Mesa Laboratories published news for 2020 q3
SEC form 6
2020-10-05 20:01 ET
Mesa Laboratories published news for 2020 q3
SEC form 6
2020-10-01 11:28 ET
Mesa Laboratories published news for 2020 q3